The Company

SeqOnce is an innovative, DeepTech company with expertise in qPCR, NGS, and novel tech development

The Genomics Market

SeqOnce was founded with a bold vision: to revolutionize Next Generation Sequencing (NGS) by making its sample preparation processes more efficient and straightforward.

Pivoting early in the Pandemic, the company developed and sold qPCR reagents for COVID tests.

Today, SeqOnce boasts a broad multi technology product portfolio designed to sustain revenue and lower barriers to market entry.  

A solid company built upon existing commercial and operations infrastructure

1. Proven experience to manage significant revenue & subsequent opportunities
2. Established customers & distributors
3. Established supply chain, and proven R&D and Clinical Teams for new assay opportunities
4. New opportunistic commercialization strategies

SeqOnce has three technology platforms/franchises 
- qPCR, NGS, & NICER

---

qPCR: Our revenue workhorse
qPCR assays for respiratory pathogens, women’s health, and pathogen screening

---

Quantitative PCR (qPCR), also known as real-time PCR, is a method that amplifies and quantifies a target DNA sequence simultaneously.

---

Next Generation Sequencing (NGS)
 RhinoSeq, A fast library prep with patent protection

---

NGS is a modern DNA sequencing technology that enables the rapid sequencing of large amounts of DNA. We developed a technology to prepare the DNA sample faster than other methods.

---

NICER (New Technology)
A new molecular biology platform to disrupt the qPCR market

---

Forecast

Completed Milestones

• Generated over $45m, with less than $1m invested
• Current revenue run rate: $100-$250k+ per month
• Invested COVID profit in R&D / new commercial lines
• Launched two new novel technologies

SeqOnce develops, manufactures, and sells genomic tools, such as PCR assays, and next generation sequencing (NGS) libraries, into large international and existing markets consisting of clinical service labs, other biotech companies, pharmaceuticals, government labs, and academic institutions. This growing revenue helps fund the R&D for both an expanding product portfolio along with the advanced research to develop the next generation of game changing technologies.

Why Do Labs Use SeqOnce Products?

• The lab business is very sticky.  Once a lab has validated a test with our reagents, the barrier to switch is costly and burdensome.
• Our assays have been optimized, well validated, and utilize established supply chains based in the USA.
• Clinical labs operate on high volume and low margin. They come to us to gain margin, and leverage off our innovative assay development team.

---

Customer Example

Recurring & Seasonal Revenue Growth

Now, building upon its deep roots in novel technology R&D, SeqOnce has developed NICER

2025 Investment Milestones / Use of Proceeds

Increase enterprise value prior to Series A priced round

• Grow Revenue
• Position company for growth
  • Establish internal manufacturing of key components, significantly expanding margins
  • Build commercial infrastructure to ramp qPCR and NGS sales
  • Commercial development opportunities for NICER
• R&D of new qPCR assays, NGS assays, and NICER
• Position company for Series A round / IPO

A strong management team with experience in BioTech

The SeqOnce team has deep expertise in genomics and molecular biology including members from Roche, Sequenom, and Agilent